InvestorsHub Logo
Followers 618
Posts 27445
Boards Moderated 3
Alias Born 11/16/2007

Re: loanranger post# 316564

Sunday, 08/02/2020 10:02:57 PM

Sunday, August 02, 2020 10:02:57 PM

Post# of 402173
Interesting...according to their press release, they changed their endpoints mid trial. Just like Gilead did with Remdesivir.

https://www.neurorxpharma.com/press-releases/press-release-phase2-3covid-19/

The study protocol enrolls patients with Critical COVID-19 and Respiratory Failure and randomly assigns them to intravenous RLF-100 or Placebo in the hopes of achieving remission from this most-serious stage of COVID-19. At the committee’s recommendation, the primary endpoint is changed to “alive and free of respiratory failure at 7-10 days.” This change in primary endpoint from mortality at 28 days is driven by the general decrease in mortality with advances in treatment for Critical COVID-19 and by initial observations in the clinical trial.


I've always thought the severe patients would be nearly impossible for anyone to treat since there appears to be a point of no return once the lung stem cells are dead and can't regenerate lung tissue.

I hope the Brilacidin trial uses a similiar endpoint to start so they don't have to change midpoint. But, I'm not the scientist.








Message in reply to:

"a small defense like peptide is showing fantastic results for Covid patients that were intubated"

https://www.neurorxpharma.com/press-releases/press-release-phase2-3covid-19/

https://clinicaltrials.gov/ct2/results?cond=&term=rlf-100&cntry=&state=&city=&dist=








To follow KarinCA, click here then click "Follow This Member" under my photo.

Be kinder than necessary, for everyone you meet is fighting some kind of battle.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News